Navigation Links
Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
Date:1/11/2008

SEATTLE, Jan. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that the Commissione Nazionale per le Societa e la Borsa ("CONSOB") granted authorization to publish the Italian listing prospectus, according to the procedures set forth by Article 8 and Article 56 of the CONSOB Regulation no. 11971/99, relating to offerings of CTI's common stock representing more than 10% of the shares of common stock currently outstanding pursuant to the Step-Up Equity Financing Agreement by and between Societe Generale and CTI, subject to the inclusion of certain additional information in the prospectus.

Societe Generale has agreed to purchase, over a period of time through January 2009, up to 60 million Euros worth of shares of CTI's common stock. Any shares issued, which are covered under an existing shelf registration, will be purchased by Societe Generale, which will sell the shares on the Italian market. Societe Generale's obligation to purchase shares upon request by CTI is subject to the conditions set forth in the agreement with the bank.

Subject to certain conditions, the Step-up Equity Financing Agreement will allow CTI to raise equity finance in one or more tranches. All issuances are at CTI's election, and CTI is not required to undertake any issuances under the agreement. The total amount of any capital raised will depend on the actual financing needs over the lifetime of the agreement and other considerations and will reflect the market performance and trading volume of CTI shares.

As soon as published, the listing prospectus will be available in hard copy form at CTI's office in Italy at Via Ariosto, 23, 20091 Bresso (MI) and at the head office of Borsa Italiana S.p.A. at Piazza degli Affari, 6, Milan; and in electronic form on CTI's web site (http://www.cticseattle.com).

About Cell Therapeutics, Inc.

Headquartered in Seattl
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
2. Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
3. Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
4. Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes
5. ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering
6. Bioenergy Life Science and Integrative Therapeutics, Inc. Form Exclusive Co-Marketing Alliance
7. Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
8. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
9. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)... 4 Researchers are taking a closer...) pathway as studies continue to demonstrate that ...growth, reports Genetic Engineering & Biotech...iogenesis, cell growth, differentiation, and survi...athway, which plays a key role in cancer, accordin...
(Date:12/4/2008)...ec. 4 Imaging Diagnostic...neer in laser optical breast,imaging, announced t...s an,adjunct to mammography is featured in the De... (Logo: http://www.newscom.com/cgi-bin/prnh/2004...radiologist at Charite Hospital in Berlin,German...
(Date:12/4/2008)...4 Raymond J. De Hont, Ch...oration (NYSE: MPR ), announced today that the Co...cember 3, 2008, declared a quarterly dividend of $...olders of record at the close of business on Febru...rease over the same period last year. , , T...
(Date:12/4/2008)...wswire/ -- Azur Pharma Limited ("Azur") today,ann...ment with BioSante,Pharmaceuticals, Inc ("BioSant...estrin(TM). Elestrin is a fast drying gel formulat...ment of moderate to severe vasomotor symptoms,ass...he U.S. Food and Drug,Administration ("FDA") in D...
Breaking Biology Technology:GEN Reports Growing Focus on PI3-Kinase Pathway in Cancer Research 2Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal 2Met-Pro Corporation Declares Quarterly Dividend 2Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM) 2
... Promega Corporation ,Source: www.promega.com F...gy companies will receive $250,000 each in tax cre... Jim Doyle announced on Tuesday. , ,Placon Corpora...r, will use the tax relief to create 19 new jobs, ...te 26, officials said. , ,Both companies are in th...
... The recent growth in popularity of two personal...cellular phones with cameras installed, has left e...liability for employers. , ,In 2002, vendors shipp...they shipped 50 million. Instant messaging has bec...gement Association and the ePolicy Institute relea...
... MILWAUKEE Before a technology entrepreneur can...ly growing business, he needs to identify one or m...gel investments. , ,This is not an easy thing to d...h community, Peter M. Skanavis is doing everything...to make angel investments to actually take the plu...
... CHICAGO In last weeks column, I raised the pre...bout making money but about providing radically ne...awn to the early years of rock n roll where it was...what was going on in society (without getting jail...oney and both have become industries that have bec...
Other Biology Technology:Is your employee handbook evolving with technology? 2Is your employee handbook evolving with technology? 3Investor profile: Peter M. Skanavis, tech angel, sees investing as civic duty 2Investor profile: Peter M. Skanavis, tech angel, sees investing as civic duty 3Investor profile: Peter M. Skanavis, tech angel, sees investing as civic duty 4Biotech IPOs bring in encouraging sums 2Biotech IPOs bring in encouraging sums 3
(Date:12/3/2008)...big and heavy, with seemingly little prayer of esc...like a grounded teenager who knows where the car k... chance of escape. , University of Florida resea... landscape devoted to wildlife corridors greenway...covered the pea and similar species share, given a...
(Date:12/3/2008)... suggests that evolution can behave as differently...rgy-efficient style of four-footed running over lo...e evolved a profoundly inefficient gait, tailor-ma..., "It is usually assumed that efficiency is what...e associate professor of evolutionary anthropology...
(Date:12/3/2008)...that individuals can respond just as well to place...ther hand, it is difficult to explain why only cer...esearchers from Uppsala University and Gothenburg ...mpact the placebo effect and a mechanism in the br...os. , The study, published in Journal of Neuros...
(Date:12/3/2008)... first tandem mission between ERS-2 and Envisat la...r again to help improve our understanding of the p...visat, the largest environmental satellite ever bu...truments that provide high resolution images of th...R images of the same site, slight alterations that...
Breaking Biology News(10 mins):Rooted plants move mysteriously down greenways, scientists say 2Rooted plants move mysteriously down greenways, scientists say 3Dogs chase efficiently, but cats skulk counterintuitively 2Genes determine whether sugar pills work 2ESA satellites flying in formation 2Ardea Biosciences Inc Reports Third Quarter 2007 Operating and Financial Results 1811 1Ardea Biosciences Inc Reports Third Quarter 2007 Operating and Financial Results 1811 2Ardea Biosciences Inc Reports Third Quarter 2007 Operating and Financial Results 1811 3Ardea Biosciences Inc Reports Third Quarter 2007 Operating and Financial Results 1811 4Ardea Biosciences Inc Reports Third Quarter 2007 Operating and Financial Results 1811 5New Research Shows Masimo Perfusion Index 28PI 29 Effective in the Noninvasive Detection of Congenital Heart Defects 28CHD 29 in Newborns 854 1New Research Shows Masimo Perfusion Index 28PI 29 Effective in the Noninvasive Detection of Congenital Heart Defects 28CHD 29 in Newborns 854 2New Research Shows Masimo Perfusion Index 28PI 29 Effective in the Noninvasive Detection of Congenital Heart Defects 28CHD 29 in Newborns 854 3New Research Shows Masimo Perfusion Index 28PI 29 Effective in the Noninvasive Detection of Congenital Heart Defects 28CHD 29 in Newborns 854 4The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 1The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 2The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 3The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 4The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 5JDRF and Lilly partner to fund research to identify beta cell biomarkers 6355 1JDRF and Lilly partner to fund research to identify beta cell biomarkers 6355 2JDRF and Lilly partner to fund research to identify beta cell biomarkers 6355 3
...c analysis of soil samples indicates that a group ...th,s most abundant land-based creatures that oxidi...researchers from Norway, Germany, United Kingdom a...ocess known as nitrification, combine ammonia with...nts by plants. , "Ammonia oxidation is an impo...
...trician well known for his care of and research in...ry changes can affect a woman,s chances of having ...y a combination of diet and heredity. By comparing...animal products, with that of women who do eat ani... physician at Long Island Jewish (LIJ) Medical Cen...
...udy, published today in the current issue of the P... significant implications for the design of diseas...ed in human biomedical research. The groundbreakin...-Substrate Interactions with Luminescent Quantum D...eplace conventional organic dyes in biomedical app...
...st research on water - still one of the least unde...ve study ?seems to support the possibility that ce...be cyropreserved without formation of damaging ice...earcher Anatoli Bogdan, Ph.D. , He conducted the s...ournal of Physical Chemistry B , one of 34 peer-re...
Other Biology News:Ammonia-loving archaea win landslide majority 2Ammonia-loving archaea win landslide majority 3Study finds that a woman's chances of having twins can be modified by diet 2Study finds that a woman's chances of having twins can be modified by diet 3Connect the Quantum Dots 2Slow-frozen people? Latest research supports possibility of cyropreservation 2
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli.
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications).
Biology Products: